Evolocumab's LDL Lowering Surpassed Inclisiran's in ORION-3

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab's greater LDL-lowering efficacy compared with inclisiran.

Related Keywords

United States ,New York ,Chicago ,Illinois ,London ,City Of ,United Kingdom ,American ,Kausikk Ray ,Roberts Rosenson , ,Amgen ,American Heart Association ,Medicines Company ,American College Of Cardiology ,Drug Administration ,Novartis ,Imperial College London ,Icahn School Of Medicine At Mount Sinai ,Lancet Diabetes ,Icahn School ,Mount Sinai ,American College ,Expert Consensus Decision Pathway ,Lipids ,Ipid Management ,Cv ,Ardiovascular ,Pcsk9 ,Roprotein Convertase Subtilisin Kexin Type 9 ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Medicare ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Grant ,Familial Hypercholesterolemia ,Low Ldl Cholesterol ,Ypobet ,